Related references
Note: Only part of the references are listed.Trastuzumab A Review of its Use as Adjuvant Treatment in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
Karly P. Garnock-Jones et al.
DRUGS (2010)
INTERNATIONAL SURVEY ON WILLINGNESS-TO-PAY (WTP) FOR ONE ADDITIONAL QALY GAINED: WHAT IS THE THRESHOLD OF COST EFFECTIVENESS?
Takeru Shiroiwa et al.
HEALTH ECONOMICS (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
Daphne T. Tsoi et al.
ONCOLOGIST (2010)
Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
Shmuel H. Klang et al.
VALUE IN HEALTH (2010)
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2009)
Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
M. Kondo et al.
BRITISH JOURNAL OF CANCER (2009)
Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan
Masahide Kondo et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies
Gary H. Lyman et al.
CANCER (2007)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith et al.
LANCET (2007)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
Paola Papaldo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Laurel A. Habel et al.
BREAST CANCER RESEARCH (2006)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
HER-2 testing and trastuzurnab therapy for metastatic breast cancer: A cost-effectiveness analysis
EB Elkin et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis
BF Cole et al.
LANCET (2001)
Share Paper
